Landscape Capital Management L.L.C. purchased a new position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 6,977 shares of the company’s stock, valued at approximately $487,000.
Several other hedge funds also recently modified their holdings of ZTS. Flossbach Von Storch SE acquired a new stake in Zoetis in the 2nd quarter worth $302,601,000. BlackRock Inc. increased its holdings in shares of Zoetis by 10.8% during the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after purchasing an additional 3,845,869 shares during the period. Ruane Cunniff & Goldfarb L.P. acquired a new position in shares of Zoetis during the first quarter valued at about $286,660,000. Southpoint Capital Advisors LP raised its position in shares of Zoetis by 340.0% during the first quarter. Southpoint Capital Advisors LP now owns 2,200,000 shares of the company’s stock valued at $260,062,000 after buying an additional 1,700,000 shares during the last quarter. Finally, Carmignac Gestion acquired a new position in shares of Zoetis during the second quarter valued at about $113,230,000. 92.80% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on ZTS shares. Jefferies Financial Group lifted their target price on Zoetis from $83.00 to $85.00 in a research report on Friday, November 6th. Weiss Ratings raised Zoetis from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, October 29th. BTIG Research dropped coverage on Zoetis in a research report on Friday, October 30th. They issued a “buy” rating and a $200.00 price objective for the company. TD Cowen decreased their price objective on Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 25th. Finally, JPMorgan Chase & Co. decreased their price objective on Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $101.25.
Check Out Our Latest Stock Analysis on ZTS
Trending Headlines about Zoetis
These are some of the ZTS headlines that stood out recently:
- Positive Sentiment: The USDA licensed Zoetis’s Poulvac® Procerta® HVT-ND-ILT, a vaccine for chickens targeting three diseases. The approval expands the company’s poultry-health portfolio and could create a commercial opportunity, though the headlines provide no sales or earnings estimates. Article: Zoetis Receives USDA License for Poulvac Procerta HVT-ND-ILT Vaccine for Chickens
- Positive Sentiment: Recent coverage also highlighted news about a dog-allergy treatment and described Zoetis shares as potentially inexpensive. The headline does not provide enough detail to assess the treatment’s likely financial impact. Article: Zoetis Stock Still Looks Cheap Following Fresh Dog Allergy Treatment News
- Neutral Sentiment: Brokerages’ consensus target price is reported at $101.25, while Barclays maintained a Hold rating—signals of potential upside in analyst estimates but also a cautious view from at least one firm. Article: Zoetis Stock Has Consensus Target Price of $101.25 According to Brokerages Article: Barclays Remains a Hold on Zoetis
Zoetis Trading Down 2.1%
Shares of ZTS stock opened at $79.09 on Friday. The firm has a fifty day moving average of $77.16 and a 200-day moving average of $90.55. The stock has a market cap of $32.14 billion, a price-to-earnings ratio of 13.45, a P/E/G ratio of 1.22 and a beta of 0.67. Zoetis Inc. has a 52-week low of $68.77 and a 52-week high of $132.49. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.40 and a current ratio of 2.35.
Zoetis (NYSE:ZTS – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $1.75 earnings per share for the quarter, beating the consensus estimate of $1.51 by $0.24. The business had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.15% and a return on equity of 85.90%. The firm’s revenue was down 1.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.70 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.29 earnings per share for the current fiscal year.
Zoetis Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis’s payout ratio is presently 36.05%.
Zoetis Profile
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
Read More
- Five stocks we like better than Zoetis
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
